



# Marksans Pharma Ltd.

Date: February 11, 2020

**BSE Limited**

Corporate Relation Department  
Phiroze Jeejeeboi Towers,  
Dalal Street,  
Mumbai – 400001.  
Scrip Code: 524404

**National Stock Exchange of India Limited**

Listing Department  
Exchange Plaza, C-1, Block-G,  
Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400051.  
Symbol: MARKSANS

**Sub: News Release**

Dear Sir,

Enclosed herewith kindly find a News Release dated February 11, 2020 of the Company.

You are requested to note the above in your records.

Thanking you.

Yours faithfully,

**For Marksans Pharma Limited**

**Harshavardhan Panigrahi**  
**Company Secretary & Manager – Legal**

**Marksans Pharma Ltd.**

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,  
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • E-mail: info@marksanspharma.com  
www.marksanspharma.com



# Marksans Pharma Ltd.

**Q3 FY20 Revenue at Rs. 287.7 Cr., EBITDA at Rs. 47.3 Cr., Net Debt at Rs. -8.1 Cr.**

**Mumbai, February 11<sup>th</sup>, 2020** – Marksans Pharma Ltd (NSE: MARKSANS; BSE Code: 524404), one of the fastest growing pharmaceutical companies in India today announced financial results for the third quarter and nine months ended December 31<sup>st</sup>, 2019.

## **Financial Highlights - Consolidated Financial Overview:**

In Rs. Cr.	Q3FY20	Q3FY19	YoY Growth (%)	YoY% (Constant currency)	9MFY20	9MFY19	YoY Growth (%)	YoY% (Constant currency)
<b>Total Revenue</b>	287.7	248.5	15.8%	24.0%	799.2	752.8	6.2%	13.7%
<b>EBITDA</b>	47.3	36.3	30.2%	39.4%	123.4	111.4	10.7%	18.6%
<b>EBITDA Margin%</b>	16.4%	14.6%	182 bps	182 bps	15.4%	14.8%	64 bps	64 bps
<b>PAT</b>	29.6	25.1	17.6%	26.0%	78.0	70.6	10.5%	18.4%
<b>PAT Margin%</b>	10.3%	10.1%	16 bps	16 bps	9.8%	9.4%	39 bps	39 bps

### **Consolidated Q3 FY20 (Y-o-Y)**

- Overall business grew by 24.0% in constant currency basis in Q3 FY20 as compared to Q3 FY19
- Total Revenue was Rs. 287.7 cr as compared to Rs. 248.5 in Q2 FY19, an increase of 15.8%
- EBITDA was Rs. 47.3 cr. as compared to Rs. 36.3 Cr. in Q3 FY19, an increase of 30.2%
- EBITDA Margin stood at 16.4% for Q3FY20 as against 14.6% in Q3FY19
- PAT stood at Rs. 29.6 cr. as compared to Rs. 25.1 cr. in Q3 FY19, a growth of 17.6%

### **Consolidated 9M FY20 (Y-o-Y)**

- Overall business grew by 13.7% in constant currency basis in 9M FY20 as compared to 9M FY19
- Total Revenue was Rs. 799.2 cr. as compared to Rs. 752.8 cr. in 9M FY19, an increase of 6.2%
- EBITDA was Rs. 123.4 Cr. as compared to Rs. 111.4 Cr. in 9MFY19, a growth of 10.7%
- EBITDA Margin stood at 15.4% for 9M FY20 as against 14.8% in 9M FY19
- PAT stood at Rs. 78.0 Cr. as compared to Rs. 70.6 Cr. in 9M FY19, an increase of 10.5%

**Commenting on the performance Mark Saldanha, Managing Director of the Company said** “We are extremely pleased with the performance of this quarter where we have exhibited strong YoY growth in revenues of almost 16% and EBITDA of 30%. We continue with our strategy of focusing on the US and UK markets by focusing on niche products with limited competition. The key highlight of this quarter is that we have become debt free and this opens up opportunities to the Company for some efficient utilization of the cash”

## Business Performance

### Revenue by Market:

in Rs. Cr.	9MFY20	9MFY19	YoY Growth (%)	YoY% (Constant currency)	Mix (9MFY20) %
Europe, UK – Formulations	360.8	323.1	11.7%	25.0%	45.2%
US & North America – Formulations	309.9	309.3	0.2%	7.3%	38.8%
Australia & NZ – Formulations	93.2	79.4	17.4%	27.7%	11.7%
Rest of World (ROW)	35.2	41.0	-14.1%	-8.0%	4.4%
<b>Consolidated Revenue from operations</b>	<b>799.2</b>	<b>752.8</b>	<b>6.2%</b>	<b>16.3%</b>	<b>100.0%</b>

### Business Highlights

- Company achieved revenue of Rs. 360.8 cr. from Europe, UK: Formulation business in 9MFY20 as compared to Rs. 323.1 cr. achieved during last year same period registering a growth of 11.7%
- US & North America Formulation business reported growth of 0.2% to Rs 309.9 cr. in 9MFY20
- Australia & NZ Formulation business revenue was at Rs. 93.2 cr. in 9MFY20, registering growth of 17.4% YoY
- Rest of World Formulation business was Rs. 35.2 cr. in 9MFY20

### About Marksans Pharma Ltd

Marksans Pharma Limited ([www.marksanspharma.com](http://www.marksanspharma.com)) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally.

For details, feel free to contact:

#### Investor Relations Team at Marksans Pharma

##### Jitendra Sharma, CFO

Marksans Pharma Ltd

Tel: +91 022 40012000

[jitendra@marksanspharma.com](mailto:jitendra@marksanspharma.com)

##### Dikshita Jain

Christensen Investor Relations

Tel : +91 22 4215 0210

[djain@christensenir.com](mailto:djain@christensenir.com)

#### Registered Office

11th Floor, "GRANDEUR"

Off Veera Desai Extension Road

Oshiwara, Andheri West

Mumbai, Maharashtra, 400 053

Telephone: +91 224001 2000

Fax: +91 224001 2011

CIN: L24110MH1992PLC066364

ISIN: INE750C01026

NSE Code: MARKSANS

BSE CODE: 524404

Website: <http://www.marksanspharma.com>